Paragon Care Limited (PXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Paragon Care Limited (PXS) has a cash flow conversion efficiency ratio of 0.031x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€7.58 Million ≈ $8.87 Million USD) by net assets (€242.34 Million ≈ $283.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PXS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Paragon Care Limited - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how Paragon Care Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Paragon Care Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Paragon Care Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arsan Tekstil Ticaret ve Sanayi AS
IS:ARSAN
|
0.015x |
|
CSU Digital S.A.
SA:CSUD3
|
-0.626x |
|
BlackRock Long-Term Municipal Advantage Trust
NYSE:BTA
|
0.021x |
|
Tecogen Inc.
NYSE:TGEN
|
-0.120x |
|
Journey Medical Corp
NASDAQ:DERM
|
-0.200x |
|
Magnachip Semiconductor Corporation
F:SMG
|
0.022x |
|
Amir Marketing and Investments in Agriculture Ltd
TA:AMRK
|
-0.002x |
|
SB Financial Group Inc
NASDAQ:SBFG
|
0.090x |
Annual Cash Flow Conversion Efficiency for Paragon Care Limited (2014–2023)
The table below shows the annual cash flow conversion efficiency of Paragon Care Limited from 2014 to 2023. For the full company profile with market capitalisation and key ratios, see Paragon Care Limited (PXS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | €251.96 Million ≈ $294.56 Million |
€17.75 Million ≈ $20.75 Million |
0.070x | -10.30% |
| 2022-06-30 | €242.34 Million ≈ $283.32 Million |
€19.03 Million ≈ $22.25 Million |
0.079x | -65.25% |
| 2021-06-30 | €121.52 Million ≈ $142.07 Million |
€27.46 Million ≈ $32.11 Million |
0.226x | +379.96% |
| 2020-06-30 | €112.28 Million ≈ $131.27 Million |
€5.29 Million ≈ $6.18 Million |
0.047x | +682.01% |
| 2019-06-30 | €192.32 Million ≈ $224.84 Million |
€1.16 Million ≈ $1.35 Million |
0.006x | -86.45% |
| 2018-06-30 | €170.14 Million ≈ $198.91 Million |
€7.56 Million ≈ $8.84 Million |
0.044x | -69.36% |
| 2017-06-30 | €82.69 Million ≈ $96.67 Million |
€11.99 Million ≈ $14.02 Million |
0.145x | +35.98% |
| 2016-06-30 | €72.77 Million ≈ $85.08 Million |
€7.76 Million ≈ $9.07 Million |
0.107x | +171.00% |
| 2015-06-30 | €20.58 Million ≈ $24.06 Million |
€809.87K ≈ $946.83K |
0.039x | +134.35% |
| 2014-06-30 | €18.21 Million ≈ $21.29 Million |
€-2.09 Million ≈ $-2.44 Million |
-0.115x | -- |
About Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provi… Read more